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Introduction
A novel flu-like coronavirus emerged from Wuhan, China in 
December 2019. It was named Severe Acute Respiratory Syndrome 
Coronavirus 2, (SARS-CoV-2), and causes Coronavirus Disease 2019, 
(COVID-19) [1]. SARS-CoV-2 rapidly spread, and on March 11th, 
2020, the WHO declared COVID-19 a pandemic [2]. As of July 3rd 
there have been 10,719,946 confirmed cases of COVID-19 worldwide, 
including 517,337 deaths, reported to the World Health Organization 
[3]. Many therapies are being investigated for their anti-viral or 
immune modulation properties to treat COVID-19, with efficacy so 
far being demonstrated for dexamethasone [4] and remdesivir [5]. 
In recent pandemics, no standardized treatments were identified for 
SARS-CoV-1, Middle East Respiratory Syndrome or Ebola, due to the 
limited number of controlled clinical trials undertaken at the time, 
with none performed on SARS-CoV-1, and only 3 and 11 for Middle 
East Respiratory Syndrome and Ebola, respectively [6]. However, 
this has been addressed for COVID-19, and there are currently 1,358 
clinical trials registered with ClinicalTrials.gov, of which 209 are 
investigating the use of convalescent plasma to treat COVD-19 [7]. 
Principles of Convalescent Plasma
Convalescent plasma is plasma, obtained from patients who 
have recovered from an infectious disease such as COVID-19, which 
contains antibodies specific to the pathogen, in this case SARS-CoV-2. 
This passive immunotherapy works by neutralizing pathogens, 
thereby decreasing the likelihood of cytokine storm occurring in 
the recipients. Convalescent plasma has been used as a therapeutic 
agent for over a hundred years. One of its earliest interventions for 
treating viral diseases was the Spanish H1N1 influenza A in 1918. 
Since then it has been used to treat Avian H5N1 influenza A epidemic 
(2003), Severe Acute Respiratory Syndrome (SARS, SARS-CoV-1) 
epidemic (2003), H1N1 influenza pandemic (2009-10), Middle East 
Respiratory Syndrome (MERS-CoV) epidemic (2012), Chikungunya, 
Ebola epidemic (2014-16) and Zika [2,3]. 
Is Convalescent Plasma Efficacious?
While it is important to await the findings for the clinical trials, 
there is some evidence that this approach will be successful. A meta-
analysis of 32 papers evaluating the efficacy of convalescent plasma 
in SARS Coronavirus patients, (699 treated versus 568 untreated 
controls), demonstrated a reduced mortality rate in the plasma arm, 
compared with placebo or no treatment (odds ratio: 0.25%; 95% CI: 
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0.14-0.45). However, many studies included in the meta-analysis were 
of poor quality, lacked control groups, and demonstrated moderate or 
high risk of bias [8]. A meta-analysis of the use of convalescent plasma 
in Spanish flu also demonstrated a reduced mortality rate [9]. There is 
some evidence about the efficacy of convalescent plasma from several 
uncontrolled case series of convalescent plasma use in COVID-19 
patients. A case-series of 5 critically ill COVID-19 patients, aged 36-65 
years, received convalescent plasma, with a SARS-CoV-2 specific IgG 
binding titre greater than 1:1000 and a neutralization titre greater than 
40, on days 10-22 following admission. The results were encouraging, 
with normalization of body temperature occurring within 3 days 
in 4 of the 5 patients. In addition, viral loads decreased and acute 
respiratory distress syndrome also resolved in 4 patients, both within 
12 days of the transfusion, and 3 patients no longer required ventilation 
within 3 weeks [10]. Duan et al. 2020 also reported an improvement 
in 10 severely affected patients who received convalescent plasma 
[11]. Viremia disappeared within 7 days, due to significantly increased 
or maintained high levels of neutralizing antibody. In addition, 
lymphocyte counts increased and C-reactive protein values decreased, 
in comparison to the pre-transfusion levels. There were also varying 
levels of adsorption of lung lesions.
Zhang et al. 2020 reported the outcomes in 4 critically ill 
COVID-19 patients, who received various quantities of convalescent 
plasma, (300, 400 and 2,400ml) [12]. All patients became RT-PCR 
negative within 3-22 days of receiving the transfusion. However, the 
contribution from other therapeutic agents administered could not 
be discerned. A retrospective, observational study involving a small 
number of participants was less promising. Despite, all 6 patients 
testing negative for SARS-CoV-2 RNA within 3 days of receiving the 
transfusion, 5 of them subsequently died. However, the patients who 
received plasma survived significantly longer than the control arm. 
The median day of transfusion was 21.5, and it was postulated this 
was too late to minimise the hyperimmune response, as the 1 patient 
who received treatment on day 11 survived [13]. Kong et al. 2020 
reported a case of a centenarian, who demonstrated improved clinical 
and laboratory findings following 2 transfusions of convalescent 
plasma, and was successfully treated by this approach [14]. In the 
study by Ahn et al. 2020, 2 COVID-19 patients who presented 
with severe pneumonia and acute respiratory distress syndrome 
demonstrated improved oxygenation, and decreased viremia and 
inflammatory markers, after the use of methylprednisolone and 
convalescent plasma [15].
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A systematic review of five studies evaluating convalescent 
plasma in COVID-19 patients demonstrated a reduced mortality rate 
in critically ill patients. In the majority of cases, an increase in the 
neutralizing antibody titres was apparent, alongside disappearance of 
SARS-CoV-2 RNA, and an improvement in clinical symptoms. This 
study concluded that convalescent plasma was an effective means of 
reducing mortality in COVID-19 [16]. A Cochrane Rapid Review 
by Valk et al. 2020 included 32 patients, from seven case-series and 
one prospectively planned study [17]. Valk et al. 2020 reported a high 
level of bias, due to the small numbers of participants, study design, 
different disease severities and varying treatments of the patients [17]. 
They were unable to perform any statistical analysis and deemed very 
low-certainty evidence for efficacy, with the data available at present 
[17]. The first randomized clinical trial evaluating convalescent 
plasma was performed in Wuhan, China. It recruited 103 participants 
with severe or life-threatening COVID-19 and compared convalescent 
plasma in addition to standard treatment (n = 52) to standard 
treatment alone (control) (n = 51). However, no statistical significant 
benefit in mortality or clinical improvement 28 days after the plasma 
transfusion in all randomized patients was observed [18]. However, 
a possible benefit was seen in the severely ill subgroup, but not the 
critically-ill group, when the data was reanalysed according to disease 
severity. The lack of statistical significance was thought to arise from 
the early termination of the trial, due to enrolment difficulties as the 
virus was being contained. This resulted in only 103 of the expected 
200 cases being recruited, which subsequently underpowered the trial 
[18]. 
Safety of Convalescent Plasma
So far the safety data for this treatment seems promising, despite 
concerns that antibody-mediated enhancement may exacerbate 
the condition via a proinflammatory effect, or complications may 
arise from transfusion-related lung injury and transfusion-related 
circulatory overload [19]. Other potential adverse events include 
breathing difficulties, transfusion transmitted infection, and 
hypersensitivity reactions, which manifest as rash, fever or chills. 
No severe adverse events were reported by Ahn et al. 2020 (n=2), 
Duan et al. 2020 (n=10), Olivares-Gazca et al. 2020 (n=10), Salazar 
et al. 2020 (n=25), Zhang et al. 2020 (n=4) or Zeng et al. 2020 (n=6) 
[11-13,15,20,21], and the meta-analysis also confirmed it was safe 
(Rajendran et al. 2020) [16], whereas Valk et al. 2020 reported very low-
certainty evidence of adverse events [17]. In the trial by Li et al. 2020 
[18], two of 52 recipients of convalescent plasma experienced adverse 
events within hours of receiving the transfusion. The chills and rash 
manifest in one of those patients suggested a transfusion reaction. The 
adverse events in both cases were managed by corticosteroids [18,22]. 
What do We Need to Know?
The controlled trials evaluating convalescent plasma will provide 
important information on the optimal dose and time to treat patients, 
donor selection, plasma collection and which patients are most likely 
to benefit. The meta-analysis on the use of convalescent plasma to treat 
Spanish flu by Luke et al. 2006 suggested that early treatment, (after 
<4 days of pneumonia complications), resulted in improved mortality 
rates than late treatment, (after ≥4 days of pneumonia complications), 
which was similar to the mortality rate among controls [9]. The study 
by Zeng et al. 2020 supports the use of convalescent plasma as an early 
intervention [13], and also by Li et al. 2020, particularly in less severely 
ill patients [18]. The concentration of donor neutralizing antibodies 
is likely to affect the efficacy, and these levels can be influenced by 
the prior treatment of the donor, such as steroids, antiviral drugs and 
intravenous immunoglobulin. It will also be interesting to explore 
convalescent plasma in combination with antiviral agents, such as 
remdisivir, due to their different mechanisms of action [22]. There is 
previous evidence that they may work well together [23]. The results 
of the many clinical trials investigating the use of convalescent plasma 
in COVID-19 are eagerly awaited, but the data from case-series and 
the use of this treatment in previous infectious diseases appears 
promising. 
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